Russia

Reimbursed Care Access

Russia maintains a restrictive, control-focused regime for classical psychedelics: most tryptamines, phenethylamines and seeded plant/tea preparations containing DMT or psilocybin are prohibited outside of sanctioned research, while ketamine is an accepted and registered medical anesthetic (and appears on national essential medicines lists). There is no broad, reimbursed medical psychedelic therapy program (no public insurance coverage for psilocybin/MDMA therapies or for esketamine as an antidepressant is not registered), and authorized access is effectively limited to licensed medical uses (e.g., ketamine anesthesia) or tightly regulated clinical research under federal narcotics law. [https://minzdrav.gov.ru/documents/8008-postanovlenie-pravitelstva-rf-681-ot-30-iyunya-1998-g|Ministry of Health — Gov. Decree No. 681] [https://grls.pharm-portal.ru/grls/90836c27-19b8-4c8d-8b39-076cb12a357d|Russian State Drug Registry (GRLS) — Ketamine entry]